Literature DB >> 33270902

A snapshot of COVID-19 infection in patients with solid tumors.

Jesús Fuentes-Antrás1, Aránzazu Manzano1,2, Gloria Marquina1, Mateo Paz1,3, Carlos Aguado1, Mónica Granja1, Javier Benítez1, Justo Ortega1, Araceli Priego1, Carlos González1, Julia Tejerina-Peces1, Paloma Flores1, Alfonso López de Sa1, Carmen Toledano1, Jennifer Olalla1, Alicia de Luna1, Jorge Bartolomé1, Pedro Pérez-Segura1.   

Abstract

Coronavirus disease 2019 (COVID-19) pandemic is affecting a high percentage of the population at an unprecedented rate. Cancer patients comprise a subgroup especially vulnerable to this infection. Herein, we present a prospective analysis of epidemiological, clinical, radiological and laboratory data of consecutive adult cancer patients seen in the Clínico San Carlos University Hospital (Madrid, Spain), and admitted to hospital and tested for COVID-19 between February 21 and May 8, 2020 due to clinical suspicion of infection. Data from 73 patients with confirmed COVID-19 and active solid tumors or diagnosed within the previous 5 years were analyzed. The most frequent malignancy was lung cancer (19%) and 54 patients (74%) were on active cancer treatment. Most common findings on presentation included cough (55%), fever (52%), and dyspnea (45%), and 32 (44%) patients showed oxygen saturation levels below 95%. Radiologically, 54 (73%) patients presented an abnormal pattern, the most frequent being infiltrates (64%). 18 (24.7%) patients died in hospital and 55 (75.3%) were discharged with clinical resolution of the event. Multivariable logistic regression adjusted for age and tumor stage showed higher odds of in-hospital death associated with a history of cardiovascular disease, hospitalization in the previous 30 days, and several features on admission including dyspnea, higher qSOFA score, higher C-reactive protein levels, and an abnormal neutrophil count. We present prospective, real-world evidence that can help articulate cancer care protocols for patients infected with SARS-CoV-2, with special focus on features on admission that can stratify patients with a higher risk of death from COVID-19. This article is protected by copyright. All rights reserved.

Entities:  

Year:  2020        PMID: 33270902     DOI: 10.1002/ijc.33420

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  2 in total

1.  Wearable sensor derived decompensation index for continuous remote monitoring of COVID-19 diagnosed patients.

Authors:  Dylan M Richards; MacKenzie J Tweardy; Steven R Steinhubl; David W Chestek; Terry L Vanden Hoek; Karen A Larimer; Stephan W Wegerich
Journal:  NPJ Digit Med       Date:  2021-11-08

Review 2.  Comprehensive adjusted outcome data are needed to assess the impact of immune checkpoint inhibitors in cancer patients with COVID-19: Results of a systematic review and meta-analysis.

Authors:  Samuel J Minkove; Junfeng Sun; Yan Li; Xizhong Cui; Diane Cooper; Peter Q Eichacker; Parizad Torabi-Parizi
Journal:  Rev Med Virol       Date:  2022-04-13       Impact factor: 11.043

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.